Gilead Sciences (NASDAQ:GILD) Given “Outperform” Rating at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Friday morning, Benzinga reports. Oppenheimer currently has a $105.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on GILD. UBS Group decreased their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a neutral rating on the stock in a research note on Wednesday. Truist Financial cut shares of Gilead Sciences from a buy rating to a hold rating and decreased their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a research note on Monday, March 4th. Royal Bank of Canada decreased their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a sector perform rating on the stock in a research note on Wednesday, February 14th. Finally, Mizuho decreased their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a buy rating on the stock in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $84.71.

Gilead Sciences Stock Up 0.9 %

Shares of GILD opened at $66.76 on Friday. Gilead Sciences has a 12 month low of $65.90 and a 12 month high of $87.86. The firm’s 50 day moving average is $71.96 and its 200-day moving average is $76.53. The stock has a market capitalization of $83.12 billion, a PE ratio of 14.84, a P/E/G ratio of 0.91 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the business posted $1.67 earnings per share. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a $0.77 dividend. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.61%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently modified their holdings of the business. PCA Investment Advisory Services Inc. bought a new position in Gilead Sciences during the second quarter worth $25,000. Tompkins Financial Corp raised its stake in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the last quarter. Private Wealth Management Group LLC bought a new position in Gilead Sciences during the fourth quarter worth $29,000. OFI Invest Asset Management bought a new position in Gilead Sciences during the third quarter worth $26,000. Finally, Fortitude Family Office LLC bought a new position in Gilead Sciences during the fourth quarter worth $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.